Top 11 CRISPR Stocks to Invest In

5. Verve Therapeutics, Inc. (NASDAQ:VERV)

Number of Hedge Fund Holders: 25

Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage biotechnology company aiming to transform cardiovascular disease treatment through innovative CRISPR-based gene-editing therapies. Its lead candidate, VERVE-101, is an in-vivo liver gene-editing therapy targeting the PCSK9 gene to reduce LDL cholesterol production by disrupting PCSK9 protein synthesis.

In November, H.C. Wainwright adjusted Verve’s stock price target to $14 from $15 while reaffirming a Buy rating. This update came after Verve Therapeutics, Inc. (NASDAQ:VERV) announced that, as of October 29, 2024, it had dosed seven patients with its second-generation PCSK9 base editor, VERVE-102, in the Phase 1b Heart-2 clinical trial. This study targets adults with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD). Initial data from the trial is anticipated in the first half of 2025.

Financially, Verve Therapeutics, Inc. (NASDAQ:VERV) reported a strong cash position of $539.9 million in Q3, sufficient to fund operations through 2026. The company recorded $6.9 million in collaboration revenue, up from $3.1 million the previous year, alongside increased R&D expenses of $49.9 million. While the quarter ended with a net loss of $50.1 million, Verve’s progress in clinical trials, financial stability, and upcoming data releases provide a promising outlook for 2025.